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BACKGROUND: In colorectal cancer (CRC), tumour microsatellite instability (MSI) status and CpG island methylator phenotype (CIMP)
status are indicators of patient outcome, but the molecular events that give rise to these outcomes remain largely unknown. Wnt5a is
a critical regulator of non-canonical Wnt activity and promoter hypermethylation of this gene has emerging prognostic roles in CRC;
however the frequency and prognostic significance of this epigenetic event have not been explored in the context of colorectal
tumour subtype. Consequently, we investigated the frequency and prognostic significance of Wnt5a methylation in a large cohort of
MSI-stratified CRCs.
METHODS: Methylation was quantified in a large cohort of 1232 colorectal carcinomas from two clinically distinct populations from
Canada. Associations were examined between methylation status and clinicopathlogical features, including tumour MSI status, BRAF
V600E mutation, and patient survival.
RESULTS: In Ontario, Wnt5a methylation was strongly associated with MSI tumours after adjustment for age, sex, and tumour location
(odds ratio (OR)¼4.2, 95% confidence interval (CI)¼2.4–7.4, Po10
 6) and with BRAF V600E mutation, a marker of CIMP
(OR¼12.3, 95% CI¼6.9–21.7, Po10
 17), but was not associated with patient survival. Concordant results were obtained in
Newfoundland.
CONCLUSION: Methylation of Wnt5a is associated with distinct tumour subtypes, strengthening the evidence of an epigenetic-mediated
Wnt bias in CRC.
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Wnt genes encode a large family of secreted glycoproteins
with widespread roles in development and carcinogenesis.
These proteins have classically been divided into canonical or
non-canonical family members based on their ability to activate
these distinct arms of the Wnt signalling network. While canonical
Wnt ligands promote cell growth and proliferation by controlling
cytoplasmic degradation and subsequently nuclear accumulation
of b-catenin. Non-canonical Wnt ligands govern cell motility
and polarity through the Wnt/calcium and/or planar cell polarity
pathways, which act through a variety of intracellular mediators
including calmodulin-dependent protein kinase II, protein kinase
C, and c-Jun N-terminal kinase. Aberrant hyperactivation of the
canonical Wnt pathway is a critical tumour-initiating event in the
majority of colorectal cancers (CRCs); however, the status of non-
canonical Wnt activity in cancer and its roles in carcinogenesis are
poorly understood. These functions have mainly been examined
through Wnt5a, the quintessential non-canonical Wnt ligand.
Wnt5a is ubiquitously expressed in normal tissues (Ying et al,
2008), but is often dysregulated in tumours (Wang et al, 2007,
2010) and has been controversially implicated in both tumour
suppression and oncogenesis in addition to being recognised as
a marker of both favourable and poor outcome in primary
cancer. Studies supporting the former have demonstrated that
Wnt5a inhibits invasion and proliferation in thyroid cancer
(Kremenevskaja et al, 2005), low expression or loss of expression
is prognostically unfavourable in breast cancer (Jonsson et al,
2002; Leris et al, 2005), and hemizygous mice develop lymphomas
(Liang et al, 2003). On the other hand, oncogenic roles have been
identified in prostate cancer, where Wnt5a promotes cell motility
(Wang et al, 2010; Yamamoto et al, 2010), melanoma, where
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sexpression associates with tumour invasion (Weeraratna et al,
2002), and hepatocellular carcinoma, where expression is asso-
ciated with poorly differentiated and invasive cell lines (Yuzugullu
et al, 2009). In CRC, Wnt5a expression has been associated with
favourable outcome in early stage tumours (Dejmek et al, 2005),
while loss of Wnt5a expression is a hallmark of CRC-derived liver
metastases (Ki et al, 2007). Collectively, these seemingly conflicting
findings underscore the poorly understood functional and
prognostic roles of Wnt5a in cancer.
Recent studies in leukaemia (Martin et al, 2010) and CRC (Ying
et al, 2008; Ahn et al, 2011) have shown that a major mechanism
for Wnt5a downregulation is promoter hypermethylation. Aber-
rant promoter hypermethylation is a hallmark of CRC that has a
pivotal role in defining tumour subtypes; somatic methylation of
the MLH1 promoter causes the majority of sporadic CRC tumours
with microsatellite instability (MSI), and widespread CpG island
methylation defines the CpG island methylator phenotype (CIMP).
Importantly, these methylation-dependent subtypes stratify dis-
ease outcome; MSI tumours are clinically favourable, but respond
poorly to 5-fluorouracil-based chemotherapy (Ribic et al, 2003;
Carethers et al, 2004), whereas CIMP tumours have complex
associations with patient outcome that may depend on MSI and/or
BRAF V600E status (Kim et al,2 0 0 9 ;O g i n oet al,2 0 0 9 ;D a h l i net al,
2010). Despite the importance of these epigenetic modifications in
defining these CRC subtypes, the specific methylation events that
contribute to subtype-specific outcome has been poorly characterised.
Our previous study suggested that microsatellite stable tumours
may exhibit preferential gain of non-canonical Wnt signalling
through methylation of Wnt antagonists (Rawson et al, 2011).
Given the importance of Wnt5a in mediating non-canonical Wnt
activity and its emerging role in carcinogenesis and prognosis, we
investigated the promoter methylation status of this gene in a large
cohort of MSI-stratified CRCs from two distinct Canadian
populations. We examined associations to patient clinicopatholo-
gical features focusing on tumour subtype and patient survival in
hopes that these relationships would provide further insight into
subtype-specific epigenetic mediation of non-canonical Wnt
signalling and would help define the prognostic role of Wnt5a
methylation in CRC.
MATERIALS AND METHODS
Study participants
Probands recruited into this study were cases of primary colorectal
carcinoma accrued through the population-based Ontario Familial
Colorectal Cancer Registry (OFCCR) and Newfoundland Familial
Colorectal Cancer Registry (NFCCR). Patient accrual, data collec-
tion, and biospecimen collection procedures at the OFCCR have
been previously detailed (Newcomb et al, 2007). Briefly, Ontario
residents diagnosed with pathology-confirmed CRC between the
ages of 20 and 74 years from 1997 to 2000 were eligible for
recruitment. Clinical data were abstracted from consenting
patients through several self-administered questionnaires and
cancer-related medical records. Pedigrees were constructed from
family history data and used to assess familial risk status according
to Amsterdam status and other criteria (Raptis et al, 2007).
Recruitment was preferential for cases with positive familial risk.
Apparent cases of familial adenomatous polyposis were excluded.
A total of 1004 probands with blood and/or tissue biospecimens were
obtained at the time of study accrual. Due to the high prevalence
of self-reported Caucasians (92.5%) and to limit the possible effects
of population stratification, we excluded non-white patients and
those with unknown or mixed ethnic background. Of the remaining
921 probands, we were able to obtain 600 tumour samples for
methylation analysis, representing 561 of these probands. Several
probands were subsequently excluded during methylation analysis
due to poor quality DNA (see section MethyLight), leading to a final
cohort of 545 Ontario cases. Annual follow-up was available for these
probands to assess vital status and recurrence.
Case selection at NFCCR was similar to that of OFCCR except for
a slightly later recruitment period (1999–2003) and the inclusion
of all incident CRC patients irrespective of family history (Green
et al, 2007). In addition, for deceased patients, NFCCR accepted
proxy consent from living family members, which led to more
frequent inclusion of late stage patients. A total of 747 probands
were recruited by NFCCR, of which 721 probands were white
(northern European origin) and had tumour samples available.
Molecular analysis was successfully performed on 687 cases after
removal of poor quality samples. An overview of patient
clinicopathological features is shown in Table 1.
Molecular analysis
Tumour and matched normal tissues were collected from surgical
specimens and embedded in paraffin. DNA was extracted (after
microdissection for Ontario patients, 470% cellularity for
tumours) and used previously to analyze MSI status, MLH1
methylation levels, and BRAF V600E mutational status.
MSI testing was performed using National Cancer Institute
guidelines, as previously described (Raptis et al, 2007). Briefly, five
or more markers were analysed from a panel consisting of: ACTC,
BAT-25, BAT-26, BAT-40, BAT-34C4, D10S197, D18S55, D2S123,
D5S346, and MYC-L. Microsatellite instability status was defined
by the number of positive markers as follows: MSI high (X30%
unstable markers), MSI low (1–29% unstable markers), or
microsatellite stable (0% unstable markers). Newfoundland
tumours that were initially characterised as MSI low were screened
for a second set of markers: BAT-40, D7S519, D17S787, D18S58,
and D20S100 (Woods et al, 2005). Due to the limited frequency of
MSI low in our population and in conjunction with the classical
definition of MSI status, tumours initially classified as MSI low
or microsatellite stable were combined and classified as ‘MSS’.
Microsatellite instability-H tumours were therefore denoted as
‘MSI’. As previously identified (Green et al, 2009), the frequency of
MSI tumours in Newfoundland was relatively low (9.9%), which
may be due, in part, to the low frequency of germline mismatch
repair mutations (Woods et al, 2005).
Status of MLH1 methylation was assessed by quantitative
MethyLight assay as previously described (Mrkonjic et al, 2010).
Positive methylation was defined as per cent methylated reference
(PMR)410. A large proportion of tumours in Newfoundland
(37.6%) were not tested due to unavailability of tumour tissue.
The somatic c.1799T4A gene mutation (p. V600E) in the BRAF
gene was analysed by allelic discrimination assay, as previously
described in Ontario (Rawson et al, 2011) and in Newfoundland
(Loughrey et al, 2007). In Ontario, 10% of samples were validated
with 100% concordance. In Newfoundland, all samples with
positive methylation were validated by direct sequencing.
Immunohistochemical staining of mismatch repair proteins
MLH1, MSH2, MSH6, and PMS2 was performed by a trained
pathologist as previously described (Lindor et al, 2002). Staining
was classified as present, absent, or inconclusive. Tumours with
absent staining in any of these proteins were defined as mismatch
repair deficient.
MethyLight
Methylation analysis was performed on matched tumour and
normal tissue using semi-quantitative MethyLight assay, a Taqman-
based technique that assesses per cent DNA methylation at a single
gene locus per reaction (Eads et al, 2000). Sodium bisulphite
treatment was performed on 50ng of sample DNA using EZ DNA
Methylation Gold kit (Zymo Research Corp., Orange, CA, USA)
according to the manufacturer’s protocol. Modified DNA was
stored at  201C until use. Primers and probes were designed to
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samplify a region within the promoter CpG island of Wnt5a as close
as possible to regions previously studied by methyl-specific PCR
(Mazieres et al, 2004; Ying et al, 2008). We also designed primers
and a probe to amplify the genomic repeat sequence Alu-C4 to
normalise for DNA amount. This is a methylation-independent
reaction and minimises amplification bias due to potential sample
aneuploidy (Weisenberger et al, 2005). Primer and probe
sequences were (Wnt5a forward) 50-TTT AGG TTC GGG CGT
TAG TGT TC -30;( Wnt5a reverse) 50-TCA AAA ACA AAA CTA
CGA AAT CCT CC-30;( Wnt5a probe) 6FAM-50-TTT AGT TTC
GGT TTA TTG CGT TCG TCG GA-30-MGBNFQ; (ALU-C4 forward)
50-GGT TAG GTA TAG TGG TTT ATA TTT GTA ATT TTA GTA-30;
(ALU-C4 reverse) 50-ATT AAC TAA ACT AAT CTT AAA CTC CTA
ACC TCA-30; (ALU-C4 probe) 6FAM-50-CCT ACC TTA ACC TCC
C-30-MGBNFQ.
Samples were analysed in 96-well plates on an ABI 7500
RT–PCR thermocycler as previously described (Weisenberger et al,
2005). Methylation was calculated as follows (Weisenberger et al,
2006): PMR¼(gene/Alu-C4)sample/(gene/Alu-C4)CpGenome 100%.
CpGenome DNA (Millipore, Billerica, MA, USA) was exogenously
methylated lymphocyte DNA that was amplified on each plate
to define a 100% reference signal for each gene. Receiver operator
curves were generated from a subset of 100 tumour-matched normal
pairs from Ontario to produce a tumour-specific methylation cutoff
(PMR¼10). This cutoff was used to define positive methylation and
is a conservative value for transcriptional silencing of other genes
(Ogino et al, 2006). For cases with multiple DNA samples due to
synchronous baseline tumours (ON: n¼34; NFLD: n¼16), PMR
values were averaged.
Validation was performed on randomly selected samples to
account for interplate variation. Per cent methylated reference
readings during validation tended to fluctuate o10% and
reassignment of methylation status was exceptionally rare. During
screening and validation, samples with an Alu-C4 threshold cycle
above 22.0 were considered poor quality, retreated with sodium
bisulphite, and subsequently reanalysed to ensure robust ampli-
fication. Samples that remained poor quality were removed from
the analysis (ON: n¼16; NFLD: n¼34).
Statistical analysis
The selectivity of Wnt5a methylation for tumour tissue over
matched normal tissue was assessed using McNemar’s w
2-test.
All univariate clinicopathological associations were assessed
by Fisher’s exact test. Multivariate modelling of MSI status was
conducted using unconditional logistic regression adjusted for age,
sex, and tumour location. Unadjusted associations to recurrence-
free survival status were assessed using Kaplan–Meier analysis
with the log-rank test. Multivariate associations to recurrence-free
survival status were conducted using a Cox regression model adjusted
f o ra g e ,s e x ,s t a g e ,a n dg r a d e ,w i t ha n dw i t h o u tM S Is t a t u s .T i m e - t o -
event was calculated from the date of diagnosis to the date of
first recurrence/death or censored at the date of last contact.
At w o - s i d e dPo0.05 was considered statistically significant. Bonfer-
roni corrections for multiple comparisons were incorporated, where
appropriate. Analysis was performed using SPSS version 16.0 (SPSS
Inc., Chicago, IL, USA).
RESULTS
Methylation analysis
We quantified promoter methylation levels of the Wnt5a gene in
545 colorectal carcinomas from Ontario and 687 colorectal
carcinomas from Newfoundland. Wnt5a was methylated in 107
(19.6%) cases in Ontario and 125 (18.2%) cases in Newfoundland
(Table 1). To verify that these methylation events were specific to
Table 1 Distribution of clinicopathological features, including Wnt5a
methylation in primary colorectal carcinomas from Ontario and Newfoundland
No. of cases (%)
Ontario Newfoundland
Cases of primary colorectal carcinoma 545 687
Mean age (s.d.) 60.7 (8.8) 61.3 (9.4)
White ethnicity 545 (100) 687 (100)
Age
o50 61 (11.2) 83 (12.1)
50+ 484 (88.8) 604 (87.9)
Sex
Female 261 (47.9) 264 (38.4)
Male 284 (52.1) 423 (61.6)
Tumour location
a
Proximal 208 (38.2) 287 (41.8)
Distal 329 (60.4) 390 (56.8)
Unavailable 8 (1.5) 10 (1.5)
TNM stage
1 95 (17.4) 101 (14.7)
2 211 (38.7) 235 (34.2)
3 165 (30.3) 206 (30.0)
4 30 (5.5) 144 (21.0)
Unavailable 44 (8.1) 1 (0.1)
Histological grade
Low 43 (7.9) 99 (14.4)
Moderate 390 (71.6) 504 (73.4)
High 63 (11.6) 71 (10.3)
Unavailable 49 (9.0) 13 (1.9)
Histological type
b
Non-mucinous 444 (81.5) 601 (87.5)
Mucinous 62 (11.4) 86 (12.5)
Unavailable 39 (7.2) 0 (0.0)
MSI status
Stable 385 (70.6) 585 (85.2)
Low 68 (12.5) 27 (3.9)
High 87 (16.0) 68 (9.9)
Unavailable 5 (0.9) 7 (1.0)
MMR germline mutation
No 178 (32.7) 670 (97.5)
Yes 15 (2.8) 17 (2.5)
Unavailable 352 (64.6)
MMR protein status
Intact 444 (81.5) 605 (88.1)
Deficient 76 (13.9) 61 (8.9)
Unavailable 25 (4.6) 21 (3.1)
MLH1 methylation
No 492 (90.3) 410 (59.7)
Yes 52 (9.5) 19 (2.8)
Untested 1 (0.2) 258 (37.6)
BRAF V600E mutation
No 463 (85.0) 568 (82.7)
Yes 63 (11.6) 77 (11.2)
Unavailable 19 (2.2) 42 (6.1)
Wnt5a methylation
Unmethylated 438 (80.4) 562 (81.8)
Methylated 107 (19.6) 125 (18.2)
Abbreviations: BRAF¼v-raf murine sarcoma viral oncogene homolog B1;
MLH1¼mutL homolog 1; MMR¼mismatch repair; MSI¼microsatellite instability;
TNM¼tumour node metastasis.
aProximal tumour location includes lesions up to
and including the splenic flexure.
bMucinous histology includes the presence of any
mucin within the tumour stroma.
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stumour tissue, we requantified Wnt5a methylation levels in
53 tumour samples in parallel with their matched normal colonic
mucosa samples (oversampling was conducted for positive tumour
methylation to increase the number of informative samples).
Wnt5a was methylated in 27 of these tumours (17 MSI, 10 MSS)
and no methylation was found in matched normal tissue.
Methylation and clinicopathological features
We examined associations between Wnt5a methylation status and
patient clinicopathological features in both populations. In
Ontario, Wnt5a methylation was much more common in MSI
tumours than in MSS tumours (odds ratio (OR)¼6.3, 95%
confidence interval (CI)¼3.9–10.4, Po10
 12) (Table 2). This
relationship was reflected in associations between Wnt5a methyla-
tion and MSI-associated tumour characteristics, including im-
munohistochemical deficiency of at least one mismatch repair
protein (OR¼7.2, 95% CI¼4.3–12.2, Po10
 12), MLH1 methyla-
tion (OR¼14.9, 95% CI¼7.8–28.5, Po10
 16), proximal location
(OR¼3.6, 95% CI¼2.3–5.6, Po10
 7), mucinous histological type
(OR¼2.0, 95% CI¼1.1–3.7, P¼0.03), and female gender
(OR¼2.5, 95% CI¼1.6–3.8, Po10
 4) (Table 2). There was,
however, no association between Wnt5a methylation and germline
mutations in mismatch repair gene, which cause the inherited MSI
tumours found in Lynch syndrome (OR¼0.3, 95% CI¼0.1–1.6,
P¼0.24). The absence of this association to Lynch-associated MSI
tumours was maintained after adjustment for age (data not
shown), indicating the absence of confounding effects due to age-
associated methylation. Indeed, Wnt5a methylation was not
associated with age X50 years compared with age o50 years
(OR¼1.5, 95% CI¼0.7–3.1, P¼0.39). Wnt5a methylation was
also strongly associated with BRAF V600E mutation (OR¼12.3,
95% CI¼6.9–21.7, Po10
 17), a common alteration in MSI and
CIMP, and this association remained after adjustment for MSI
status (OR¼7.9, 95% CI¼4.2–14.7, Po10
 10).
An identical analysis was conducted in our validation cohort
from Newfoundland. Wnt5a methylation was similarly associated
with MSI tumours (OR¼5.0, 95% CI¼3.0–8.4, Po10
 18) and
the same set of MSI-associated characteristics: MMR IHC
deficiency (OR¼6.2, 95% CI¼6.6–10.7, Po10
 9), MLH1 methy-
lation (OR¼36.7, 95% CI¼10.3–130.4, Po10
 10), proximal
location (OR¼3.2, 95% CI¼2.1–4.9, Po10
 7), mucinous histo-
logical type (OR¼1.9, 95% CI¼1.1–3.2, P¼0.02), and female
gender (OR¼1.6, 95% CI¼1.1–2.3, P¼0.03) (Table 2). Wnt5a
methylation remained unassociated with age X50 years (OR¼1.7,
95% CI¼0.9–3.4, P¼0.13), but showed a borderline inverse
association with germline MMR gene mutation – no methylated
cases carried these mutations, whereas 17 unmethylated cases (3%)
carried these mutations (P¼0.05). Wnt5a methylation also
remained strongly associated with BRAF V600E before (OR¼
Table 2 Associations between Wnt5a methylation and age, sex, MSI status, MSI-associated features, and BRAF V600E status
Ontario Newfoundland
Unmethylated
(%)
Methylated
(%)
OR
(95% CI) P
Unmethylated
(%)
Methylated
(%)
OR
(95% CI) P
Age
o50 52 (11.9) 9 (8.4) 1.0 0.39 73 (13.0) 10 (8.0) 1.0 0.13
50+ 386 (88.1) 98 (91.6) 1.5 (0.7, 3.1) 489 (87.0) 115 (92.0) 1.7 (0.9, 3.4)
Sex
M 247 (56.4) 37 (34.6) 1.0 5.90 10
 5* 357 (63.5) 66 (52.8) 1.0 0.03
F 191 (43.6) 70 (65.4) 2.5 (1.6, 3.8) 205 (36.5) 59 (47.2) 1.6 (1.1, 2.3)
Location
Distal 291 (67.2) 38 (36.5) 1.0 2.21 10
 8* 347 (62.9) 43 (34.4) 1.0 1.20 10
 8*
Proximal 142 (32.8) 66 (63.5) 3.6 (2.3, 5.6) 205 (37.1) 82 (65.6) 3.2 (2.1, 4.9)
Histological type
Non-mucinous 365 (89.5) 79 (80.6) 1.0 0.03 500 (89.0) 101 (80.8) 1.0 0.02
Mucinous 43 (10.5) 19 (19.4) 2.0 (1.1, 3.7) 62 (11.0) 24 (19.2) 1.9 (1.1, 3.2)
MSI status
MSS 390 (90.1) 63 (58.9) 1.0 7.56 10
 13* 521 (93.5) 93 (74.4) 1.0 7.24 10
 19*
MSI 43 (9.9) 44 (41.1) 6.3 (3.9, 10.4) 36 (6.5) 32 (25.6) 5.0 (3.0, 8.4)
MMR protein status
Intact 382 (91.6) 62 (60.2) 1.0 2.83 10
 13* 513 (94.7) 92 (74.2) 1.0 2.81 10
 10*
Deficient 35 (8.4) 41 (39.8) 7.2 (4.3, 12.2) 29 (5.3) 32 (25.8) 6.2 (3.6, 10.7)
MMR germline mutation
No 123 (90.4) 55 (96.5) 1.0 0.24 545 (97.0) 125 (100.0) 1.0 0.05
Yes 13 (9.6) 2 (3.5) 0.3 (0.1, 1.6) 17 (3.0) 0 (0.0) —
MLH1 methylation
No 492 (90.4) 70 (65.4) 1.0 1.08 10
 17* 358 (99.2) 52 (76.5) 1.0 2.06 10
 11*
Yes 52 (9.6) 37 (34.6) 14.9 (7.8, 28.5) 3 (0.8) 16 (23.5) 36.7 (10.3, 130.4)
BRAF V600E
No 405 (94.6) 60 (58.8) 1.0 2.61 10
 18* 508 (96.4) 60 (50.8) 1.0 5.78 10
 33*
Yes 23 (5.4) 42 (41.2) 12.3 (6.9, 21.7) 19 (3.6) 58 (49.2) 25.9 (14.4, 46.3)
Abbreviations: BRAF¼v-raf murine sarcoma viral oncogene homolog B1; CI¼confidence interval; MMR¼mismatch repair; MSI¼microsatellite instability; MSS¼microsatellite stable;
OR¼odds ratio; TNM¼tumour node metastasis. *Significant P-value after Bonferroni correction (Po5.55 10
 3). — OR cannot be computed due to zero cell count.
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s25.9, 95% CI¼14.4–46.3, Po10
 33) and after (OR ¼20.9, 95%
CI¼11.4–38.5, Po10
 21) adjustment for MSI status.
Methylation status of Wnt5a was weakly associated or not
associated with several other clinicopathological characteristics in
one population, including: pathological N and M substages, local
invasion, patient history of irritable bowel syndrome, and patient
history of inflammatory bowel disease (Supplementary Table 1).
Notably, however, Wnt5a methylation increased with grade in both
populations and trended towards an association with increasing
tumour stage and, more specifically, pathological T substage in
Newfoundland (Supplementary Table 1).
Methylation and multivariate MSI
We constructed a multivariate MSI model to adjust for the possible
confounders of age, sex, and tumour location (Table 3). These
covariates were each individually associated with MSI status in
both populations (data not shown). After adjustment for these
factors, Wnt5a methylation remained strongly associated with MSI
in both Ontario (OR¼4.2, 95% CI¼2.4–7.5, Po10
 6) and
Newfoundland (OR¼3.8, 95% CI¼2.2–6.6, Po10
 5).
Methylation and recurrence-free survival
To assess the prognostic role of Wnt5a methylation, we conducted
recurrence-free survival analysis. In Ontario, there were 120
recurrences and/or deaths due to CRC with a mean interval of
30 months from diagnosis. The mean follow-up time among
remaining cases was 97 months. Wnt5a methylation was not
significantly associated with outcome in unadjusted analysis
(HR¼0.7, 95% CI¼0.4–1.1, P¼0.13) or after adjustment for
age, sex, stage, and grade (HR¼0.8, 95% CI¼0.5–1.4, P¼0.42).
A similar analysis was conducted in Newfoundland, where there
were 244 recurrences and/or deaths with a mean interval of 26
months from diagnosis. The mean follow-up time among
remaining cases was 65 months. Again, Wnt5a methylation was
not associated with outcome in unadjusted analysis (HR¼1.0, 95%
CI¼0.7–1.4, P¼0.83) or after adjustment for age, sex, stage, and
grade (HR¼0.8, 95% CI¼0.6–1.2, P¼0.28).
To assess the potential effects of MSI status on these relation-
ships, we verified that MSI was a prognosticator of favourable
outcome in both Ontario (HR¼0.3, 95% CI¼0.2–0.7, P¼0.002)
and Newfoundland (HR¼0.5, 95% CI¼0.3–0.8, P¼0.007) and
subsequently added an MSI covariate to the multivariate survival
model. After this additional adjustment for MSI status, there was
clearly no association between Wnt5a methylation and patient
outcome in either Ontario (HR¼1.0, 95% CI¼0.6–1.7, P¼0.96)
or Newfoundland (HR¼0.9, 95% CI¼0.6–1.3, P¼0.53).
DISCUSSION
Wnt5a is emerging as an important functional and prognostic
contributor in several cancers and is commonly silenced by
promoter hypermethylation. In CRC, DNA methylation has a vital
role in defining prognostic subtypes, and aberrant Wnt signalling
is critical for carcinogenesis; however, the prevalence of Wnt5a
methylation in CRC and its distribution among tumour subtypes is
poorly understood. In an effort to determine the frequency of this
event between CRC subtypes and its potential prognostic role, we
examined Wnt5a promoter methylation levels in two distinct MSI-
stratified Canadian populations: Ontario, a heterogeneous popula-
tion with a moderate incidence of CRC, and Newfoundland, a
founder population with a high incidence of CRC, particularly
within families (Woods et al, 2005). Despite these differences,
Wnt5a methylation was concordantly observed in approximately
20% of tumours from both population. This is a lower methylation
frequency than previously reported in two small CRC series from
East Asia (Ying et al, 2008; Ahn et al, 2011). Wnt5a methylation
was absent from a subset of matched normal mucosa, verifying
that this event is tumour specific.
Importantly, this event was unequally distributed among MSI
subtypes; Wnt5a methylation was much more common in MSI
tumours than in MSS tumours in both populations and these
associations were independent of the combined effects of patient
age, sex, and tumour location. Furthermore, Wnt5a methylation
was strongly associated with MLH1 methylation, the primary cause
of sporadic MSI, but not associated with germline MMR gene
mutations, which cause the inherited MSI tumours found in Lynch
Syndrome. Consequently, Wnt5a appears to be preferentially
methylated among sporadic MSI tumours compared with HNPCC-
associated MSI tumours.
Wnt5a methylation was also strongly associated with the
oncogenic BRAF V600E mutation, a surrogate marker of CIMP
high (Ogino and Goel, 2008) that correlates with a distinct subset
of CIMP-associated methylation markers (Tanaka et al, 2010).
BRAF V600E is an independent prognosticator of poor outcome in
CRC and seems to be important confounder to the prognostic roles
of CIMP (Kim et al, 2009; Ogino et al, 2009). Combined status of
BRAF V600E, CIMP, and MSI has been proposed to more
accurately stratify prognostic groups in CRC (Kim et al, 2009;
Ogino et al, 2009; Dahlin et al, 2010). The strong and independent
associations of Wnt5a methylation with both MSI and BRAF
V600E suggest that this event may be a marker of MSI/CIMP-high
tumours, which seem to be a particularly favourable CRC subset in
these studies. Since promoter methylation of Wnt5a induces
transcriptional silencing in CRC cells (Ying et al, 2008), our results
suggest that MSI and/or CIMP-high tumours may experience
preferential repression of non-canonical Wnt activity. These
findings extend our previous results that suggested MSS tumours
may be preferentially permissive to non-canonical Wnt stimula-
tion due to the methylation status of Wnt antagonist genes
(Rawson et al, 2011). Consequently, multiple epigenetic events
may promote differential non-canonical Wnt stimulation between
CRC subtypes.
In addition to its effects on non-canonical Wnt activity, Wnt5a
is also known to inhibit b-catenin accumulation in CRC cells (Ying
et al, 2008; Yuzugullu et al, 2009), suggesting that MSI and/or
CIMP-high tumours may also experience preferential activation of
canonical Wnt activity. This may be particularly important during
Table 3 Multivariate MSI analysis adjusted for age, sex, tumour location, and Wnt5a methylation status
Ontario Newfoundland
Variable Univariate P Multivariate P Multivariate OR (95% CI) Univariate P Multivariate P Multivariate OR (95% CI)
Age 0.95 0.16 0.98 (0.95, 1.01) 0.06 0.002 0.96 (0.94, 0.99)
Female Sex 0.003 0.27 1.36 (0.79, 2.35) 0.05 0.31 1.33 (0.77, 2.29)
Proximal Location 4.37 10
 15 7.82 10
 12 8.41 (4.57, 15.47) 1.31 10
 12 7.74 10
 8 6.21 (3.19, 12.09)
Wnt5a Meth 7.56 10
 15 6.94 10
 7 4.22 (2.39, 7.45) 7.24 10
 9 3.94 10
 6 3.78 (2.15, 6.64)
Abbreviations: CI¼confidence interval; MSI¼microsatellite instability; OR¼odds ratio.
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sdevelopment of MSI and CIMP tumours due to the relative absence
of APC mutation as a means to induce cytoplasmic b-catenin
accumulation in these tumours (Thorstensen et al, 2005; Samowitz
et al, 2007; Albuquerque et al, 2010). Promoter methylation of the
DKK1 gene, which encodes a pivotal antagonist of the canonical
Wnt pathway, has already been strongly associated with MSI
(Rawson et al, 2011), begging the question whether canonical Wnt
activity may be primarily driven by upstream epigenetic changes
rather than downstream genetic changes in this subset of CRCs.
Further investigation of the epigenetic status of other Wnt
regulatory genes between CRC subtypes will be necessary to
scrutinise this hypothesis.
Despite the attractive downstream effects of Wnt5a on cell
signaling, the impact of subtype-associated Wnt5a methylation
on subtype-specific CRC outcome is unclear. By offering both
tumour-suppressive and oncogenic effects, the opposing regula-
tory functions of Wnt5a on canonical and non-canonical Wnt
pathways may obscure the prognostic role of Wnt5a methylation
in our analysis and help explain the conflicting results obtained in
other cancers. Indeed, it has been proposed that these discordant
functions of Wnt5a may affect CRC prognosis in a time-dependent
manner, whereby early Wnt5a expression exerts a favourable effect
by inhibiting tumour growth through canonical Wnt suppression,
whereby late expression of Wnt5a exerts a deleterious effect
by promoting tumour invasion through non-canonical Wnt
activation (Wang, 2009). This model is harmonious with the
identification of Wnt5a expression as a marker of favourable
outcome in early CRC (Dejmek et al, 2005). Since methylation was
well represented in both early and late stage tumours within our
populations, this may help explain the absence of a significant
association to recurrence-free survival despite the strong associa-
tion to MSI. In addition, the prognostic relevance of Wnt5a
methylation may be confounded by the status of downstream
canonical and non-canonical Wnt mediators that may influence
the signalling response to Wnt5a loss. Importantly, these
effects may also be related to tumour subtype since alterations
in canonical Wnt components seem to vary with MSI status
(Thorstensen et al, 2005; Ortega et al, 2008; Albuquerque et al,
2010), although subtype specificity in non-canonical Wnt pathway
components has not been explored.
To our knowledge, this is the first study to identify an
association between Wnt5a methylation and cancer subtype. These
findings extend the perspective that epigenetic events may promote
differential Wnt signalling between tumour subtypes. Determining
the exact functional and prognostic significant of these events may
rely on investigating the collective genetic and epigenetic status of
other Wnt mediators in the context of tumour subtype.
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